MannKind: New Approvals Majorly Increase MannKind's Prospects (NASDAQ:MNKD)
· seekingalpha.com
Three revenue streams continue to feed modest growth for MannKind Corporation. Read more on MNKD stock here and why it is a Strong Buy.
This is my first article on MannKind ( MNKD ), a developing commercial stage biotech with an ~$1.3 billion market cap. MannKind is enjoying a catalyst-rich 2026...